tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Apogee Therapeutics price target raised to $87 from $78 at BofA

BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics (APGE) to $87 from $78 and keeps a Buy rating on the shares, citing estimate changes following Q2 results and rolling forward its base valuation year to 2026.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1